Skip to Main Content

The three major pathophysiologic causes of thrombocytosis are (1) clonal, including essential (or primary) thrombocythemia and other myeloproliferative disorders; (2) familial, including rare cases of nonclonal myeloproliferation resulting from thrombopoietin and thrombopoietin receptor mutations; and (3) reactive, in which thrombocytosis occurs secondary to a variety of acute and chronic clinical conditions.

Acronyms and Abbreviations

Acronyms and abbreviations that appear in this chapter include: EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; FGF, fibroblast growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; LIF, leukemia inhibitory factor; SCF, stem cell factor; SDF, stromal cell-derived factor; STAT, signal transducer and activator of transcription; TPO, thrombopoietin.

The upper limit of the normal platelet count in most clinical laboratories is between 350,000/μL (350 × 109/L) and 450,000/μL (450 × 109/L). In a sample of 10,000 healthy individuals 18 to 65 years of age, 1 percent had platelet counts greater than 400,000/μL. Only in 8 these 99 individuals was thrombocytosis confirmed 6 months to 1 year later.1 Nevertheless, it is clear that thrombocytosis is a feature of several important disorders, including cancer, and that even a high normal platelet count is associated with morbidity and mortality. In a longitudinal study of healthy Norwegian men, a platelet count in the top quartile of the normal range was associated with a twofold increase in cardiovascular mortality over a 12-year followup.2 Whether the platelet count per se, or an underlying inflammatory condition resulting in both thrombocytosis and accelerated atherogenesis is responsible for these observations is not certain. The causes of thrombocytosis in which the platelet count exceeds the upper limit can be broadly categorized as (1) reactive, or secondary; (2) clonal, including essential thrombocythemia and other myeloproliferative disorders; and (3) familial (see Table 87–1). This chapter focuses on the causes and molecular mechanisms that underlie reactive, or secondary, thrombocytosis. Clonal and familial thrombocytosis are discussed in detail in Chap. 87.

The regulation of platelet production is discussed extensively in Chap. 113, but a brief discussion here will serve to provide the appropriate background for discussion of reactive thrombocytosis. Thrombopoietin (TPO), the ligand for the megakaryocytic growth factor receptor c-mpl, is the major humoral regulator of megakaryocyte survival, growth, and development, although, curiously, it does not stimulate the final step in thrombopoiesis, platelet release from megakaryocyte proplatelet processes. Although TPO supports the entire continuum of megakaryocyte development from stem cell to mature megakaryocyte,3 other cytokines including interleukin [IL]-6,4 IL-3,5,6IL-11,7 leukemia inhibitory factor (LIF),8,9 fibroblast growth factor (FGF)-4,10 stromal cell-derived factor (SDF)-1,10,11interferon (IFN)-γ ,12 and granulocyte-macrophage colony-stimulating factor (GM-CSF)13 also affect thrombopoiesis, both in vitro and in vivo. Many of these cytokines act in synergy with other cytokines, including TPO.11,12,14

The regulation of thrombopoiesis occurs primarily by humoral ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.